Showing results (21-30 of 109) with videos related to
Sort By:
Pageof 11
Journal of Drugs in Dermatology : JDD|June 9, 2016
Two Randomized, Double-Blind, Split-Face Studies to Compare the Irritation Potential of Two Topical Acne Fixed Combinations Over a 21-Day Treatment PeriodNeal Bhatia, Varsha Bhatt, Gina Martin, et al.Journal of Cutaneous Medicine and Surgery|January 7, 2014
Therapeutic options for external genital wartsRonald Vender, Marc Bourcier, Neal Bhatia, et al.Journal of Cutaneous Medicine and Surgery|January 7, 2014
Managing external genital warts: practical aspects of treatment and preventionMarc Bourcier, Neal Bhatia, Charles Lynde, et al.Journal of Cutaneous Medicine and Surgery|January 7, 2014
Understanding genital warts: epidemiology, pathogenesis, and burden of disease of human papillomavirusNeal Bhatia, Charles Lynde, Ronald Vender, et al.Journal of Drugs in Dermatology : JDD|August 3, 2007
Myeloid sarcoma presenting as an isolated nodule in a patient with acute myelogenous leukemiaNeal Bhatia, Timothy Wallace, Ajit Divgi, et al.Journal of Drugs in Dermatology : JDD|March 6, 2023
Breaking the Frustrating Cycle of Topical Steroids in Psoriasis: A Review of a Novel Vehicle for Fixed-Dose Combination Halobetasol Propionate/TazaroteneLeon Kircik, Neal Bhatia, Edward Lain, et al.Journal of Cutaneous Medicine and Surgery|January 7, 2014
Clinical features of external genital wartsCharles Lynde, Ronald Vender, Marc Bourcier, et al.Journal of Drugs in Dermatology : JDD|August 9, 2023
Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 StudyJayme Heim, J Gabriel Vasquez, Brad Schenkel, et al.The Journal of Clinical and Aesthetic Dermatology|November 16, 2022
Effective Treatment of Inflammatory Lesions of Rosacea with Subantibiotic Dose Doxycycline Irrespective of Patient Weight or Baseline Lesion Count SeverityJames Q Del Rosso, Jean Philippe York, Neal BhatiaThe Journal of Dermatological Treatment|May 11, 2023
Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysisNeal Bhatia, Jayme Heim, Brad Schenkel, et al.Pageof 11